


Biased Signaling in Physiology,
Pharmacology and
Therapeutics




Edited by
Brian J. Arey



BIASED SIGNALING IN PHYSIOLOGY, PHARMACOLOGY AND THERAPEUTICS

Edited by

BRIAN J. AREY



AMSTERDAM • BOSTON • HEIDELBERG • LONDON
NEW YORK • OXFORD • PARIS • SAN DIEGO
SAN FRANCISCO • SINGAPORE • SYDNEY • TOKYO

Academic Press is an imprint of Elsevier



Academic Press is an imprint of Elsevier
525 B Street, Suite 1800, San Diego, CA 92101-4495, USA
32 Jamestown Road, London NW1 7BY, UK
225 Wyman Street, Waltham, MA 02451, USA

Copyright © 2014 Elsevier Inc. All rights reserved.

No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or any information storage and retrieval system, without permission in writing from the publisher. Details on how to seek permission, further information about the Publisher's permissions policies and our arrangements with organizations such as the Copyright Clearance Center and the Copyright Licensing Agency, can be found at our website: www.elsevier.com/permissions.

This book and the individual contributions contained in it are protected under copyright by the Publisher (other than as may be noted herein).

Notices

Knowledge and best practice in this field are constantly changing. As new research and experience broaden our understanding, changes in research methods, professional practices, or medical treatment may become necessary.

Practitioners and researchers must always rely on their own experience and knowledge in evaluating and using any information, methods, compounds, or experiments described herein. In using such information or methods they should be mindful of their own safety and the safety of others, including parties for whom they have a professional responsibility.

To the fullest extent of the law, neither the Publisher nor the authors, contributors, or editors, assume any liability for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein.

British Library Cataloguing-in-Publication Data

A catalogue record for this book is available from the British Library

Library of Congress Cataloging-in-Publication Data

A catalog record for this book is available from the Library of Congress

ISBN: 978-0-12-411460-9

For information on all Academic Press publications
visit our website at <http://store.elsevier.com/>

Typeset by MPS Limited, Chennai, India
www.adi-mps.com

Printed and bound in the United States of America

14 15 16 17 18 10 9 8 7 6 5 4 3 2 1



Working together
to grow libraries in
developing countries

www.elsevier.com • www.bookaid.org

BIASED SIGNALING IN PHYSIOLOGY, PHARMACOLOGY AND THERAPEUTICS

Dedication

This book is dedicated to my wife Tiffany, my sons James and Alexander and my stepson Nicholas. You have been my inspiration, motivation and refuge; I am eternally grateful.

...I will conclude with an hypothesis which – in its simplest message argues that biological communication consists of a complex meshwork of structures in which G proteins, surface receptors, the extracellular matrix, and the vast cytoskeletal network within cells are joined in a community of effort, for which my life and those of my colleagues is a metaphor.

Martin Rodbell 1994 Nobel Lecture

Preface

As a beginning to this book, I would like to take a brief moment to explain the motivation and objectives of this text. The ultimate objective of the book is to provide a single but comprehensive source of information (for both personal and educational purposes) concerning signal transduction as it is understood in the present with the addition of a personal vision on receptor signaling.

The first chapter is purposefully basic and intended to provide both a general historical backdrop and description of basic pharmacological principles as a launching point to the more detailed descriptions of other topics provided by my co-authors. As the focus of the book is on common themes in receptor signaling across classes of receptors, there are natural redundancies apparent from chapter to chapter. With limited space, we have attempted to provide a comprehensive view of the field including understanding how we can model and assess signaling bias in the practical sense. I am motivated to put these topics together in order to provide a more complete view of how we envision receptor signaling and to put it in the context of evolution and a more universal view of receptor signaling. That is, despite clear and significant differences between classes of receptors, there are also universal principles to their function that have been selected and carried forward throughout evolution.

As this book is published, it occurs to me that the concepts of biased signaling are just coming to the popular forefront of the minds of the research world. However, in my mind, the contents of this book are a culmination of my thoughts and my journey in science.

There are several key moments in the development of these thoughts on signal transduction and the potential of multiple signaling outputs provided by activated receptors. The first being the observations made by my fellow graduate student, Tom Burris, in the late 1980s that dopamine could not only inhibit prolactin secretion from isolated anterior pituitary cells through Gi activation but also stimulate it through a Gs mechanism, and the discussions that followed within the lab that included Marc Freeman (my graduate advisor) and Béla Kanyicska. My exposure to research in nuclear receptors and the development of selective estrogen and progesterone receptor modulators at Wyeth also had a profound impact on my views since it was through this research that I came to the realization that cell background and associated proteins provided another level of regulation and possibilities for the development of better therapeutics. Lastly, the observation that naturally occurring ligands could also induce signaling bias in collaboration with Francisco López (on glycoprotein hormone receptors) and the development of synthetic biased agonists to the FSH and calcium-sensing receptors have rounded out this view.

In compiling this resource, I have sought out fellow authors who are well-respected experts in their domains and who have had significant impact on their research fields for the topics they provided. I would like to thank them for their commitment to this project and for the outstanding chapters they have written. It is my sincere hope that you, the reader, will find this book useful and compelling.

Brian J. Arey M.S., Ph.D.

*Department of Cardiovascular Drug Discovery Biology,
Research and Development, Bristol-Myers Squibb Company, Hopewell, NJ, USA*

Biased Signaling in Physiology, Pharmacology and Therapeutics is accompanied by a website featuring discussion questions, summaries, full color images and additional resources compiled by the authors. To access these companion resources, please visit <http://booksite.elsevier.com/9780124114609>.

About the Editor

Brian J. Arey received the Bachelor of Science degree in biology from Saint Louis University where as an undergraduate he performed research on estrogen and progesterone receptors and their interactions with chromatin. He then moved to Florida State University where he received both Master's and Doctorate degrees studying neuroendocrine physiology with Dr. Marc Freeman.

In 1992, his work in graduate school led to an National Institutes of Health (NIH) Postdoctoral Fellowship in the NIH Center for Reproductive Sciences at Northwestern University, where he studied the expression and signaling mechanisms of the mouse and rat prolactin receptors.

While at Wyeth in the mid-1990s, Dr. Arey collaborated to develop some of the first described allosteric agonists, antagonists and partial agonists to the follicle-stimulating hormone receptor (FSHR). As part of this research he was the first to demonstrate that the FSH receptor could activate multiple G-protein signaling pathways. In addition, he proposed the concepts of biased agonism/conformational dynamics as a natural physiological phenomenon in relation to glycoprotein hormone receptors.

Dr. Arey ultimately moved to Bristol-Myers Squibb where he and his colleagues developed allosteric modulators to a number of other receptors including novel allosteric modulators to the calcium-sensing receptor (CaSR). Throughout his tenure in pharmaceutical research, he has contributed to the discovery or development of multiple marketed medicines. Dr. Arey writes reviews and is requested to speak internationally on the topics of allosteric activation of GPCRs and the role of biased signaling.



List of Contributors

- Andrew Alt** Lead Discovery and Optimization, Research and Development, Bristol-Myers Squibb Company, Wallingford, CT, USA
- Brian J. Arey** Department of Cardiovascular Drug Discovery Biology, Research and Development, Bristol-Myers Squibb Company, Hopewell, NJ, USA
- Barbara Bosier** Institute of Neuroscience, Group of Neuropharmacology, Université Catholique de Louvain, Brussels, Belgium
- Thomas P. Burris** Department of Pharmacological and Physiological Science, Saint Louis University School of Medicine, St. Louis, MO, USA
- Colin A. Flaveny** Department of Pharmacological and Physiological Science, Saint Louis University School of Medicine, St. Louis, MO, USA
- Emmanuel Hermans** Institute of Neuroscience, Group of Neuropharmacology, Université Catholique de Louvain, Brussels, Belgium
- James Herrington** Department of Exploratory Biology and Genomics, Research and Development, Bristol-Myers Squibb Company, Wallingford, CT, USA
- Terry Kenakin** Department of Pharmacology, University of North Carolina School of Medicine, NC, USA
- Douglas J. Kojetin** Department of Molecular Therapeutics, The Scripps Research Institute, Jupiter, FL, USA
- Luciano Mueller** Leads Discovery and Optimization, Research and Development, Bristol-Myers Squibb Company, Princeton, NJ, USA
- Guillermo G. Romero** Department of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
- Liang Schweizer** Leads Discovery and Optimization, Research and Development, Bristol-Myers Squibb Company, Princeton, NJ, USA
- Laura A. Solt** Department of Molecular Therapeutics, The Scripps Research Institute, Jupiter, FL, USA
- John Watson** Lead Discovery and Optimization, Research and Development, Bristol-Myers Squibb Company, Wallingford, CT, USA

Contents

Preface	xi
About the Editor	xiii
List of Contributors	xv

1. An Historical Introduction to Biased Signaling 1

BRIAN J. AREY

Introduction	1
Isolation and Characterization of Receptors	3
Mechanisms of Receptor Function	10
Basic Principles of Receptor Pharmacology	19
Conformational Dynamics and Biased Signaling	26
Physiological and Therapeutic Implications of Biased Signaling	34
Conclusion	36
References	36

2. The Role of the Cell Background in Biased Signaling 41

GUILLERMO G. ROMERO

Biased Signaling	41
Receptor Interacting Proteins: Defining the Receptor Interactome	43
G Protein-Coupled Receptors	47
Receptor Tyrosine Kinases	61
The Microenvironment	68
Conclusion	71
References	71

3. The Application of Signaling Bias to New Therapeutic Drug Therapy for Seven Transmembrane (G Protein-coupled) Receptors: Quantifying Bias 81

TERRY KENAKIN

Introduction	81
Defining the Pathways: β -Arrestin-Mediated Signaling	82
What is Signaling Bias?	84
The Quantification of Biased Signaling	87
Predicting Signaling Bias <i>In Vivo</i>	95

Physiological Relevance of Signaling Bias	97
Conclusion	98
References	99

4. Biased Signaling and Conformational Dynamics in Nuclear Hormone Receptors 103

COLIN A. FLAVENY, LAURA A. SOLT, DOUGLAS J. KOJETIN AND THOMAS P. BURRIS

Nuclear Receptors	104
Nuclear Receptor Activation	105
Nuclear Receptor Co-Factors	106
Nuclear Receptor Modulators	106
The "Helix 12 Switch" Model	107
Dynamic Features of Graded Receptor Agonism	108
Nuclear Receptor Conformational Dynamics and Drug Discovery	109
Nuclear Receptor Selective Modulators	111
Conclusion	126
References	126

5. Biasing Receptor Tyrosine Kinase Signaling Pathways 137

JOHN WATSON, BRIAN J. AREY AND ANDREW ALT

Introduction	137
Biased Ligands of Receptor Tyrosine Kinases	145
Biased Signaling By RTK Antagonists	158
Conclusion	162
Acknowledgments	164
References	164

6. Conformational Mechanisms of Signaling Bias of Ion Channels 173

JAMES HERRINGTON AND BRIAN J. AREY

Introduction	174
Ion Channel Overview	175
Ion Channel Structures	178
Conformational Dynamics	183
Allosteric Modulation of Ion Channels	187
Biased Signaling By Ion Channels	190
Conclusion	199
References	199

7. Protein Conformational Dynamics and Signaling in Evolution and Pathophysiology 209

LIANG SCHWEIZER AND LUCIANO MUELLER

Introduction	210
The Role of Protein Conformational Dynamics in Evolution	217

Aberrant Protein Conformation and Associated Diseases	228
Therapeutic Strategies Against Protein Conformational Aberration	237
Conclusion	240
References	240

8. Promises of Biased Signaling in the Development of Improved Therapeutics 251

BARBARA BOSIER AND EMMANUEL HERMANS

Introduction	252
“Mechanisms” of Biased Signaling	253
Biased Signaling in Pathophysiology	264
Biased Signaling Holds Promise for Drug Development	266
Trends to Understand Bias and Implications in Pharmaceutical Design	272
Existing Therapies with Biased Signaling Carrying Putative Clinical Relevance	277
Conclusion	280
References	280

Index 293

